-
1
-
-
0037831023
-
The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R)
-
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
-
(2003)
JAMA
, vol.289
, pp. 3095-105
-
-
Kessler, R.C.1
Berglund, P.2
Demler, O.3
-
3
-
-
0037493499
-
Cost of lost productive work time among US workers with depression
-
Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA 2003;289:3135-44
-
(2003)
JAMA
, vol.289
, pp. 3135-44
-
-
Stewart, W.F.1
Ricci, J.A.2
Chee, E.3
-
4
-
-
64949165379
-
Treatment-resistant depression and mortality after acute coronary syndrome
-
Carney RM, Freedland KE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 2009;166:410-17
-
(2009)
Am J Psychiatry
, vol.166
, pp. 410-17
-
-
Carney, R.M.1
Freedland, K.E.2
-
5
-
-
34248381347
-
Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods
-
Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54
-
(2007)
Can J Psychiatry
, vol.52
, pp. 46-54
-
-
Berlim, M.T.1
Turecki, G.2
-
7
-
-
33751338530
-
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report
-
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
-
(2006)
Am J Psychiatry
, vol.163
, pp. 1905-17
-
-
Rush, A.J.1
Trivedi, M.H.2
Wisniewski, S.R.3
-
8
-
-
33749049165
-
A comparison of lithium and T3 augmentation following two failed medication treatments for depression: A STAR*D report
-
quiz 665
-
Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;16:1519-1530; quiz 665
-
(2006)
Am J Psychiatry
, vol.16
, pp. 1519-1530
-
-
Nierenberg, A.A.1
Fava, M.2
Trivedi, M.H.3
-
9
-
-
85047695030
-
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report
-
Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-72
-
(2006)
Am J Psychiatry
, vol.163
, pp. 1161-72
-
-
Fava, M.1
Rush, A.J.2
Wisniewski, S.R.3
-
10
-
-
66249105682
-
Utility of atypical antipsychotics in the treatment of resistant unipolar depression
-
DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009;23:369-77
-
(2009)
CNS Drugs
, vol.23
, pp. 369-77
-
-
Debattista, C.1
Hawkins, J.2
-
11
-
-
69949087539
-
Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials
-
Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91
-
(2009)
Am J Psychiatry
, vol.166
, pp. 980-91
-
-
Nelson, J.C.1
Papakostas, G.I.2
-
12
-
-
71449089682
-
Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: A review of registration trials
-
McIntyre RS, Muzina DJ, Adams A, et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009;10:3061-75
-
(2009)
Expert Opin Pharmacother
, vol.10
, pp. 3061-75
-
-
McIntyre, R.S.1
Muzina, D.J.2
Adams, A.3
-
13
-
-
77956421518
-
Quetiapine XR: Current status for the treatment of major depressive disorder
-
Pae CU, Sohi MS, Seo HJ, et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1165-73
-
(2010)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.34
, pp. 1165-73
-
-
Pae, C.U.1
Sohi, M.S.2
Seo, H.J.3
-
14
-
-
0019976616
-
Major tranquillisers used as antidepressants. A review
-
Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982;4:173-93
-
(1982)
J Affect Disord
, vol.4
, pp. 173-93
-
-
Robertson, M.M.1
Trimble, M.R.2
-
15
-
-
0035902983
-
Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile
-
Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201
-
(2001)
Eur J Pharmacol
, vol.425
, pp. 197-201
-
-
Schmidt, A.W.1
Lebel, L.A.2
Howard Jr., H.R.3
Zorn, S.H.4
-
16
-
-
29344438343
-
Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety
-
Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):30-40
-
(2005)
J Clin Psychiatry
, vol.66
, Issue.SUPPL. 8
, pp. 30-40
-
-
Blier, P.1
Szabo, S.T.2
-
18
-
-
54049141721
-
Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
-
Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008;60:358-403
-
(2008)
Pharmacol Rev
, vol.60
, pp. 358-403
-
-
Lieberman, J.A.1
Bymaster, F.P.2
Meltzer, H.Y.3
-
19
-
-
0034049108
-
Depression: The case for a monoamine deficiency
-
Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000;61(Suppl 6):7-11
-
(2000)
J Clin Psychiatry
, vol.61
, Issue.SUPPL. 6
, pp. 7-11
-
-
Delgado, P.L.1
-
20
-
-
60149086219
-
Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A
-
Shelton RC, Sanders-Bush E, Manier DH, Lewis DA. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 2009;158:1406-15
-
(2009)
Neuroscience
, vol.158
, pp. 1406-15
-
-
Shelton, R.C.1
Sanders-Bush, E.2
Manier, D.H.3
Lewis, D.A.4
-
21
-
-
73549116494
-
5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants
-
Richardson-Jones JW, Craige CP, Guiard BP, et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010;65:40-52
-
(2010)
Neuron
, vol.65
, pp. 40-52
-
-
Richardson-Jones, J.W.1
Craige, C.P.2
Guiard, B.P.3
-
22
-
-
2142715377
-
How antidepressants help depression: Mechanisms of action and clinical response
-
Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. J Clin Psychiatry 2004;65(Suppl 4):25-30
-
(2004)
J Clin Psychiatry
, vol.65
, Issue.SUPPL. 4
, pp. 25-30
-
-
Delgado, P.L.1
-
23
-
-
0034635825
-
SNaRIs NaSSAs and NaRIs: New agents for the treatment of depression
-
Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-18
-
(2000)
Lancet
, vol.355
, pp. 911-18
-
-
Kent, J.M.1
-
24
-
-
0041932292
-
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways
-
Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
-
(2003)
J Pharmacol Exp Ther
, vol.306
, pp. 954-64
-
-
Millan, M.J.1
Gobert, A.2
Lejeune, F.3
-
25
-
-
72149119722
-
A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: Approaching early-onset antidepressants
-
Pandey DK, Mahesh R, Kumar AA, et al. A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol Biochem Behav 2010;94:363-73
-
(2010)
Pharmacol Biochem Behav
, vol.94
, pp. 363-73
-
-
Pandey, D.K.1
Mahesh, R.2
Kumar, A.A.3
-
26
-
-
4444260616
-
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression
-
Celada P, Puig M, Amargos-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252-65
-
(2004)
J Psychiatry Neurosci
, vol.29
, pp. 252-65
-
-
Celada, P.1
Puig, M.2
Amargos-Bosch, M.3
-
27
-
-
1642293910
-
The selective norepinephrine reuptake inhibitor antidepressant reboxetine: Pharmacological and clinical profile
-
Hajos M, Fleishaker JC, Filipiak-Reisner JK, et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004;10:23-44
-
(2004)
CNS Drug Rev
, vol.10
, pp. 23-44
-
-
Hajos, M.1
Fleishaker, J.C.2
Filipiak-Reisner, J.K.3
-
29
-
-
0034007549
-
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
-
Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65
-
(2000)
Depress Anxiety
, vol.11
, pp. 58-65
-
-
Corrigan, M.H.1
Denahan, A.Q.2
Wright, C.E.3
-
30
-
-
1542344432
-
Ziprasidone: A novel psychotropic with unique properties
-
Ballas C, Yang C, O'Reardon J, et al. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004;4:179-86
-
(2004)
Expert Rev Neurother
, vol.4
, pp. 179-86
-
-
Ballas, C.1
Yang, C.2
O'Reardon, J.3
-
31
-
-
49549104014
-
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity
-
Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:2303-12
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 2303-12
-
-
Jensen, N.H.1
Rodriguiz, R.M.2
Caron, M.G.3
-
33
-
-
68949141678
-
Antipsychotic drug actions on gene modulation and signaling mechanisms
-
Molteni R, Calabrese F, Racagni G, et al. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009;124:74-85
-
(2009)
Pharmacol Ther
, vol.124
, pp. 74-85
-
-
Molteni, R.1
Calabrese, F.2
Racagni, G.3
-
34
-
-
0037215386
-
Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs
-
Bai O, Chlan-Fourney J, Bowen R, et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71:127-31
-
(2003)
J Neurosci Res
, vol.71
, pp. 127-31
-
-
Bai, O.1
Chlan-Fourney, J.2
Bowen, R.3
-
35
-
-
2342451962
-
Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus
-
Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004;1010:81-6
-
(2004)
Brain Res
, vol.1010
, pp. 81-6
-
-
Bai, O.1
Zhang, H.2
Li, X.M.3
-
36
-
-
27744496919
-
Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress
-
Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005;1063:32-9
-
(2005)
Brain Res
, vol.1063
, pp. 32-9
-
-
Luo, C.1
Xu, H.2
Li, X.M.3
-
37
-
-
77649274917
-
Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression
-
Yoshimura R, Ikenouchi-Sugita A, Hori H, et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:308-12
-
(2010)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.34
, pp. 308-12
-
-
Yoshimura, R.1
Ikenouchi-Sugita, A.2
Hori, H.3
-
38
-
-
41949107744
-
Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence
-
Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367-88
-
(2008)
CNS Drugs
, vol.22
, pp. 367-88
-
-
Pae, C.U.1
Serretti, A.2
Patkar, A.A.3
Masand, P.S.4
-
40
-
-
34347335477
-
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study
-
Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53
-
(2007)
J Clin Psychiatry
, vol.68
, pp. 843-53
-
-
Berman, R.M.1
Marcus, R.N.2
Swanink, R.3
-
41
-
-
40949089056
-
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study
-
Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65
-
(2008)
J Clin Psychopharmacol
, vol.28
, pp. 156-65
-
-
Marcus, R.N.1
McQuade, R.D.2
Carson, W.H.3
-
42
-
-
0018425438
-
A new depression scale designed to be sensitive to change
-
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
-
(1979)
Br J Psychiatry
, vol.134
, pp. 382-9
-
-
Montgomery, S.A.1
Asberg, M.2
-
45
-
-
71649092568
-
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies
-
Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 2010;120:133-40
-
(2010)
J Affect Disord
, vol.120
, pp. 133-40
-
-
Nelson, J.C.1
Mankoski, R.2
Baker, R.A.3
-
46
-
-
60349130186
-
Adjunctive aripiprazole in major depressive disorder: Analysis of efficacy and safety in patients with anxious and atypical features
-
Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008;69:1928-36
-
(2008)
J Clin Psychiatry
, vol.69
, pp. 1928-36
-
-
Trivedi, M.H.1
Thase, M.E.2
Fava, M.3
-
47
-
-
66849141289
-
Aripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressants
-
Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206
-
(2009)
CNS Spectr
, vol.14
, pp. 197-206
-
-
Berman, R.M.1
Fava, M.2
Thase, M.E.3
-
49
-
-
38349106715
-
Aripiprazole monotherapy in nonpsychotic bipolar i depression: Results of 2 randomized, placebo-controlled studies
-
Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
-
(2008)
J Clin Psychopharmacol
, vol.28
, pp. 13-20
-
-
Thase, M.E.1
Jonas, A.2
Khan, A.3
-
50
-
-
77954138432
-
Safety and tolerability of adjunctive aripiprazole in major depressive disorder: A pooled post hoc analysis (studies CN138-139 and CN138-163)
-
Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009;11:344-52
-
(2009)
Prim Care Companion J Clin Psychiatry
, vol.11
, pp. 344-52
-
-
Nelson, J.C.1
Thase, M.E.2
Trivedi, M.H.3
-
51
-
-
68449095067
-
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: A pooled analysis of 2 studies
-
Fava M, Wisniewski SR, Thase ME, et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol 2009;29:362-7
-
(2009)
J Clin Psychopharmacol
, vol.29
, pp. 362-7
-
-
Fava, M.1
Wisniewski, S.R.2
Thase, M.E.3
-
52
-
-
77954679900
-
Safety considerations of the use of second generation antipsychotics in the treatment of major depression: Extrapyramidal and metabolic side effects
-
Debattista C, Debattista K. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr Drug Saf 2010;5:263-6
-
(2010)
Curr Drug Saf
, vol.5
, pp. 263-6
-
-
Debattista, C.1
Debattista, K.2
-
53
-
-
70449704967
-
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: Review of efficacy, safety, and study design issues
-
Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat 2009;5:369-83
-
(2009)
Neuropsychiatr Dis Treat
, vol.5
, pp. 369-83
-
-
Bobo, W.V.1
Shelton, R.C.2
-
54
-
-
76949088866
-
Olanzapine/ fluoxetine: A review of its use in patients with treatment-resistant major depressive disorder
-
Croxtall JD, Scott LJ. Olanzapine/ fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010;24:245-62
-
(2010)
CNS Drugs
, vol.24
, pp. 245-62
-
-
Croxtall, J.D.1
Scott, L.J.2
-
55
-
-
0035169876
-
A novel augmentation strategy for treating resistant major depression
-
Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4
-
(2001)
Am J Psychiatry
, vol.158
, pp. 131-4
-
-
Shelton, R.C.1
Tollefson, G.D.2
Tohen, M.3
-
56
-
-
27544509056
-
Olanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistance
-
Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289-97
-
(2005)
J Clin Psychiatry
, vol.66
, pp. 1289-97
-
-
Shelton, R.C.1
Williamson, D.J.2
Corya, S.A.3
-
57
-
-
33750374140
-
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression
-
Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-72
-
(2006)
Depress Anxiety
, vol.23
, pp. 364-72
-
-
Corya, S.A.1
Williamson, D.2
Sanger, T.M.3
-
58
-
-
33847681848
-
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
-
Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-36
-
(2007)
J Clin Psychiatry
, vol.68
, pp. 224-36
-
-
Thase, M.E.1
Corya, S.A.2
Osuntokun, O.3
-
59
-
-
3242716826
-
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features
-
Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004;24:365-73
-
(2004)
J Clin Psychopharmacol
, vol.24
, pp. 365-73
-
-
Rothschild, A.J.1
Williamson, D.J.2
Tohen, M.F.3
-
60
-
-
68149125187
-
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD)
-
Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009;66:838-47
-
(2009)
Arch Gen Psychiatry
, vol.66
, pp. 838-47
-
-
Meyers, B.S.1
Flint, A.J.2
Rothschild, A.J.3
-
61
-
-
0026877917
-
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
-
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
-
(1992)
Med Care
, vol.30
, pp. 473-83
-
-
Ware Jr., J.E.1
Sherbourne, C.D.2
-
62
-
-
64149130671
-
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression
-
Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009;70:387-96
-
(2009)
J Clin Psychiatry
, vol.70
, pp. 387-96
-
-
Trivedi, M.H.1
Thase, M.E.2
Osuntokun, O.3
-
63
-
-
77951058334
-
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: Rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies
-
Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010;71:451-62
-
(2010)
J Clin Psychiatry
, vol.71
, pp. 451-62
-
-
Tohen, M.1
Case, M.2
Trivedi, M.H.3
-
64
-
-
33646501208
-
Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis
-
Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 2006;188:410-5
-
(2006)
Br J Psychiatry
, vol.188
, pp. 410-5
-
-
Wijkstra, J.1
Lijmer, J.2
Balk, F.J.3
-
65
-
-
16844384048
-
Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone?
-
Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am J Psychiatry 2005;162:796-8
-
(2005)
Am J Psychiatry
, vol.162
, pp. 796-8
-
-
Parker, G.1
Brotchie, H.2
Parker, K.3
-
66
-
-
0344551192
-
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study
-
Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003;64:1349-56
-
(2003)
J Clin Psychiatry
, vol.64
, pp. 1349-56
-
-
Corya, S.A.1
Andersen, S.W.2
Detke, H.C.3
-
67
-
-
10744220918
-
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar i depression
-
Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
-
(2003)
Arch Gen Psychiatry
, vol.60
, pp. 1079-88
-
-
Tohen, M.1
Vieta, E.2
Calabrese, J.3
-
68
-
-
28844469344
-
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
-
Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005;66:1468-76
-
(2005)
J Clin Psychiatry
, vol.66
, pp. 1468-76
-
-
Andersen, S.W.1
Clemow, D.B.2
Corya, S.A.3
-
69
-
-
36049015484
-
Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study
-
McIntyre A, Gendron A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007;24:487-94
-
(2007)
Depress Anxiety
, vol.24
, pp. 487-94
-
-
McIntyre, A.1
Gendron, A.2
-
70
-
-
54449093654
-
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
-
Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008;23:269-75
-
(2008)
Int Clin Psychopharmacol
, vol.23
, pp. 269-75
-
-
Garakani, A.1
Martinez, J.M.2
Marcus, S.3
-
71
-
-
66349134744
-
Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study
-
Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
-
(2009)
J Clin Psychiatry
, vol.70
, pp. 540-9
-
-
Bauer, M.1
Pretorius, H.W.2
Constant, E.L.3
-
72
-
-
77956440952
-
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study
-
El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:917-32
-
(2010)
Int J Neuropsychopharmacol
, vol.13
, pp. 917-32
-
-
El-Khalili, N.1
Joyce, M.2
Atkinson, S.3
-
73
-
-
53149092475
-
The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial
-
Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 2008;8:73
-
(2008)
BMC Psychiatry
, vol.8
, pp. 73
-
-
Chaput, Y.1
Magnan, A.2
Gendron, A.3
-
74
-
-
70149093635
-
Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study
-
Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14:299-313
-
(2009)
CNS Spectr
, vol.14
, pp. 299-313
-
-
Weisler, R.1
Joyce, M.2
McGill, L.3
-
75
-
-
66349094570
-
Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study
-
Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-39
-
(2009)
J Clin Psychiatry
, vol.70
, pp. 526-39
-
-
Cutler, A.J.1
Montgomery, S.A.2
Feifel, D.3
-
76
-
-
78649676124
-
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study
-
published online 9 August 2010, doi:10.1016/j.jad.2010.06.031
-
Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2010:published online 9 August 2010 doi:10.1016/j.jad.2010.06.031
-
(2010)
J Affect Disord
-
-
Bortnick, B.1
El-Khalili, N.2
Banov, M.3
-
77
-
-
78649524734
-
Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD)
-
Vienna Austria
-
Earley W, McIntyre A, Wang G, et al. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). 8th International Forum on Mood and Anxiety Disorders. Vienna, Austria; 2008. p. P10
-
(2008)
8th International Forum on Mood and Anxiety Disorders
-
-
Earley, W.1
McIntyre, A.2
Wang, G.3
-
78
-
-
78649522704
-
Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD)
-
Vienna Austria
-
Katila H, Mezhebovsky I, Mulroy A, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD). 8th International Forum on Mood and Anxiety Disorders. Vienna, Austria; 2008. p. P23
-
(2008)
8th International Forum on Mood and Anxiety Disorders
-
-
Katila, H.1
Mezhebovsky, I.2
Mulroy, A.3
-
79
-
-
78649499136
-
Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: A randomized, placebo-controlled trial
-
Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010;27:964-76
-
(2010)
Depress Anxiety
, vol.27
, pp. 964-76
-
-
Liebowitz, M.1
Lam, R.W.2
Lepola, U.3
-
80
-
-
76449083788
-
Treatment of unipolar psychotic depression: A randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine
-
Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010;121:190-200
-
(2010)
Acta Psychiatr Scand
, vol.121
, pp. 190-200
-
-
Wijkstra, J.1
Burger, H.2
Van Den Broek, W.W.3
-
81
-
-
41549159758
-
Quetiapine monotherapy for bipolar depression
-
Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 2008;4:11-21
-
(2008)
Neuropsychiatr Dis Treat
, vol.4
, pp. 11-21
-
-
Thase, M.E.1
-
82
-
-
77953500268
-
Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study
-
Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-20
-
(2010)
Int J Neuropsychopharmacol
, vol.13
, pp. 305-20
-
-
Bandelow, B.1
Chouinard, G.2
Bobes, J.3
-
83
-
-
70349337426
-
Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders
-
Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009;9:1147-58
-
(2009)
Expert Rev Neurother
, vol.9
, pp. 1147-58
-
-
Gao, K.1
Sheehan, D.V.2
Calabrese, J.R.3
-
84
-
-
33750212103
-
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
-
Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006;31:2505-13
-
(2006)
Neuropsychopharmacology
, vol.31
, pp. 2505-13
-
-
Rapaport, M.H.1
Gharabawi, G.M.2
Canuso, C.M.3
-
85
-
-
38449106889
-
Risperidone for treatment-refractory major depressive disorder: A randomized trial
-
Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007;147:593-602
-
(2007)
Ann Intern Med
, vol.147
, pp. 593-602
-
-
Mahmoud, R.A.1
Pandina, G.J.2
Turkoz, I.3
-
86
-
-
38549087763
-
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression
-
Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008;16:21-30
-
(2008)
Am J Geriatr Psychiatry
, vol.16
, pp. 21-30
-
-
Alexopoulos, G.S.1
Canuso, C.M.2
Gharabawi, G.M.3
-
87
-
-
49649096422
-
Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study
-
Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:1228-336
-
(2008)
J Clin Psychiatry
, vol.69
, pp. 1228-336
-
-
Reeves, H.1
Batra, S.2
May, R.S.3
-
88
-
-
57749198414
-
A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression
-
Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43:205-14
-
(2009)
J Psychiatr Res
, vol.43
, pp. 205-14
-
-
Keitner, G.I.1
Garlow, S.J.2
Ryan, C.E.3
-
90
-
-
49549104016
-
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation'
-
author reply 2548
-
Carroll BJ. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation'. Neuropsychopharmacology 2008;33:2546-7; author reply 2548
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 2546-7
-
-
Carroll, B.J.1
-
91
-
-
55849129650
-
Ziprasidone in the treatment of affective disorders: A review
-
Rosa AR, Franco C, Torrent C, et al. Ziprasidone in the treatment of affective disorders: a review. CNS Neurosci Ther 2008;14:278-86
-
(2008)
CNS Neurosci Ther
, vol.14
, pp. 278-86
-
-
Rosa, A.R.1
Franco, C.2
Torrent, C.3
-
92
-
-
1842855918
-
Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder
-
Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217-21
-
(2004)
J Clin Psychiatry
, vol.65
, pp. 217-21
-
-
Papakostas, G.I.1
Petersen, T.J.2
Nierenberg, A.A.3
-
93
-
-
34548299095
-
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study
-
Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007;68:1071-7
-
(2007)
J Clin Psychiatry
, vol.68
, pp. 1071-7
-
-
Dunner, D.L.1
Amsterdam, J.D.2
Shelton, R.C.3
-
94
-
-
0036047459
-
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder
-
Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43
-
(2002)
World J Biol Psychiatry
, vol.3
, pp. 5-43
-
-
Bauer, M.1
Whybrow, P.C.2
Angst, J.3
-
95
-
-
34247890186
-
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care
-
Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007;8:67-104
-
(2007)
World J Biol Psychiatry
, vol.8
, pp. 67-104
-
-
Bauer, M.1
Bschor, T.2
Pfennig, A.3
-
97
-
-
70350051602
-
-
London, UK: National Institute for Health and Clinical Excellence Available from [Last accessed 6 November 2010]
-
Depression: the treatment and management of depression in adults. London, UK: National Institute for Health and Clinical Excellence. 2009. Available from: www.nice.org.uk/ CG90 [Last accessed 6 November 2010]
-
(2009)
Depression: The Treatment and Management of Depression in Adults
-
-
-
98
-
-
69649095792
-
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy
-
Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
-
(2009)
J Affect Disord
, vol.117
, Issue.SUPPL. 1
-
-
Lam, R.W.1
Kennedy, S.H.2
Grigoriadis, S.3
-
99
-
-
77951226602
-
Major depressive disorder treatment guidelines in America and Europe
-
Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010;71(Suppl E1):e04
-
(2010)
J Clin Psychiatry
, vol.71
, Issue.SUPPL. E1
-
-
Davidson, J.R.1
-
100
-
-
0008489062
-
-
American Psychiatric Association, American Psychiatric Association, Washington, DC
-
Kane JM, Jeste DV, Barnes TR, et al. Tardive Dyskinesia a Task Force Report of the American Psychiatric Association. American Psychiatric Association, Washington, DC; 1992
-
(1992)
Tardive Dyskinesia A Task Force Report of the
-
-
Kane, J.M.1
Jeste, D.V.2
Barnes, T.R.3
-
101
-
-
40949136198
-
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review
-
Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28:203-9
-
(2008)
J Clin Psychopharmacol
, vol.28
, pp. 203-9
-
-
Gao, K.1
Kemp, D.E.2
Ganocy, S.J.3
-
102
-
-
67049162787
-
Akathisia: An updated review focusing on second-generation antipsychotics
-
Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-43
-
(2009)
J Clin Psychiatry
, vol.70
, pp. 627-43
-
-
Kane, J.M.1
Fleischhacker, W.W.2
Hansen, L.3
-
103
-
-
77649217019
-
Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies
-
Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010;67:220-9
-
(2010)
Arch Gen Psychiatry
, vol.67
, pp. 220-9
-
-
Luppino, F.S.1
De Wit, L.M.2
Bouvy, P.F.3
-
104
-
-
59749102688
-
Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap
-
McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009;9:51-9
-
(2009)
Curr Diab Rep
, vol.9
, pp. 51-9
-
-
McIntyre, R.S.1
Rasgon, N.L.2
Kemp, D.E.3
-
105
-
-
68149182296
-
Major depression and coronary artery disease in the Swedish twin registry: Phenotypic, genetic, and environmental sources of comorbidity
-
Kendler KS, Gardner CO, Fiske A, Gatz M. Major depression and coronary artery disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of comorbidity. Arch Gen Psychiatry 2009;66:857-63
-
(2009)
Arch Gen Psychiatry
, vol.66
, pp. 857-63
-
-
Kendler, K.S.1
Gardner, C.O.2
Fiske, A.3
Gatz, M.4
-
106
-
-
3342901698
-
Physical health monitoring of patients with schizophrenia
-
Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
-
(2004)
Am J Psychiatry
, vol.161
, pp. 1334-49
-
-
Marder, S.R.1
Essock, S.M.2
Miller, A.L.3
-
107
-
-
0037227192
-
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
-
Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
-
(2003)
Arch Gen Psychiatry
, vol.60
, pp. 82-91
-
-
Meltzer, H.Y.1
Alphs, L.2
Green, A.I.3
-
108
-
-
33845934245
-
Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study
-
Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006;28:1912-21
-
(2006)
Clin Ther
, vol.28
, pp. 1912-21
-
-
Ward, A.1
Ishak, K.2
Proskorovsky, I.3
Caro, J.4
-
109
-
-
33747185865
-
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study
-
Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333(7561):224
-
(2006)
BMJ
, vol.333
, Issue.7561
, pp. 224
-
-
Tiihonen, J.1
Wahlbeck, K.2
Lonnqvist, J.3
-
110
-
-
34447133528
-
Safety and usage of atypical antipsychotic medicines in children: A nationwide prospective cohort study
-
Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf 2007;30:569-79
-
(2007)
Drug Saf
, vol.30
, pp. 569-79
-
-
Harrison-Woolrych, M.1
Garcia-Quiroga, J.2
Ashton, J.3
Herbison, P.4
-
111
-
-
26844538114
-
Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials
-
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43
-
(2005)
JAMA
, vol.294
, pp. 1934-43
-
-
Schneider, L.S.1
Dagerman, K.S.2
Insel, P.3
|